# 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs

> **NCT01842165** · PHASE3 · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 37 (actual)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumors

## Interventions

- **DRUG:** Intravenous injection of 177Lu-octreotate

## Key facts

- **NCT ID:** NCT01842165
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-09-19
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01842165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01842165, "177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01842165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*